Abstract
BACKGROUND. Transgenic mice that recapitulate the progression of human diseases are potentially useful models for testing the effectiveness of new therapeutic strategies. Their use in pre-clinical testing of adenovirally-delivered gene therapies, however, is limited because of restricted cell surface expression of Coxsackie adenovirus receptor (CAR) in mice. METHODS. To develop a more suitable transgenic mouse model for testing adenoviral-based gene therapies for prostate cancer, we generated prostate specific antigen/human CAR (PSA/hCAR) transgenic mice in which a chimeric enhancer/promoter sequence of the human PSA gene drives expression of a functional hCAR coding sequence. RESULTS. Expression of an adenovirally- delivered luciferase reporter gene in prostate tumor cells in bigenic mice (PSA/hCAR + TRAMP) was enhanced compared to the level in tumor cells lacking the PSA/hCAR transgene. CONCLUSIONS. Breeding PSA/hCAR mice to existing transgenic mouse models for prostate cancer (e.g., TRAMP) results in improved mouse models for testing adenovirally-delivered therapeutic genes.
Original language | English (US) |
---|---|
Pages (from-to) | 401-407 |
Number of pages | 7 |
Journal | Prostate |
Volume | 64 |
Issue number | 4 |
DOIs | |
State | Published - Sep 1 2005 |
Externally published | Yes |
Keywords
- Adenoviral vector
- Coxsackie adenoviral receptor
- Gene therapy
- Prostate cancer
- Transgenic mice
ASJC Scopus subject areas
- Urology